$FENC News

HC Wainwright & Co. Maintains Buy on Fennec Pharmaceuticals, Raises Price Target to $16

Fennec Pharmaceuticals (NASDAQ:FENC) Q1 Beat Overshadowed by Surging Costs

Fennec Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript

Fennec Pharmaceuticals Announces Acceptance of Abstracts at the 2026 ASCO Annual Meeting

Wedbush Refines Fennec Pharmaceuticals Estimates Ahead of Q1 Earnings

Wedbush Reiterates Outperform on Fennec Pharmaceuticals, Maintains $13 Price Target

Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center

Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fennec Pharmaceuticals Grants 377500 Stock Options To 24 New Employees Under Nasdaq Inducement Rule 5635 C 4

Fennec Pharmaceuticals Grants 377500 Stock Options To 24 New Employees Under Nasdaq Inducement Rule 5635 C 4

Companies Like Fennec Pharmaceuticals (NASDAQ:FENC) Can Afford To Invest In Growth

Fennec Pharmaceuticals Inc. Q4 2025 Earnings Call Summary

Fennec Pharmaceuticals Inc (FENC) Q4 2025 Earnings Call Highlights: Record Sales and Strategic ...

Adherex Technologies Q4 Earnings Call Highlights

Fennec Pharmaceuticals (NASDAQ:FENC) Reports Q4 2025 Revenue Growth but Misses Earnings Estimates

Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Fennec Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q4 financial results.

Fennec Pharmaceuticals Q4 GAAP EPS $(0.17) Misses $0.04 Estimate, Sales $13.777M Miss $13.993M Estimate

Fennec Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026